In an open‑label phase II trial of intranasal racemic ketamine (50–150 mg) given over one week to 20 advanced‑cancer palliative care patients with moderate–severe major depressive disorder, 70% achieved ≥50% MADRS response and 45% achieved remission by Day 8, with mean MADRS falling from 31 to 11 (p<0.001) and partial maintenance to Day 14. Treatment was feasible and generally well tolerated—adverse effects were mostly mild and transient—supporting larger randomised controlled trials.
- Published
- Journal
- Cancers
- Authors
- Al Kindy, A., deVries, F. E., Doyle, Z., Hannon, B., Li, M., Mak, E., McIntyre, R. S., Patel, Z., Rodin, G., Rosenblat, J. D., Schulz-Quach, C., Zimmermann, C.